Related Experiment Videos
Generalized lipodystrophy, congenital and acquired (lipoatrophy)
1Department of Paediatrics, Rikshospitalet, National Hospital, Oslo, Norway.
Acta Paediatrica (Oslo, Norway : 1992). Supplement
|June 1, 1996
Summary
Congenital generalized lipodystrophy causes severe insulin resistance from birth, leading to metabolic complications and early mortality. Acquired lipodystrophy is an autoimmune condition with similar metabolic issues.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Genetics
Background:
- Lipodystrophy is characterized by a lack of adipose tissue, impacting energy storage.
- Congenital generalized lipodystrophy (CGL) presents with severe metabolic derangements from birth.
- Acquired generalized lipodystrophy (AGL) is considered an autoimmune disorder affecting adipose tissue.
Observation:
- Patients with CGL exhibit insulin resistance, hyperinsulinemia, dyslipidemia, and insulin-resistant diabetes.
- Clinical manifestations include increased height velocity in children, organomegaly, and hypertrophic cardiomyopathy.
- AGL involves secondary metabolic complications, including anabolic syndrome and insulin-resistant diabetes.
Findings:
- Inability to store energy in adipose tissue is central to lipodystrophy pathogenesis.
- CGL is recessively inherited, potentially linked to insulin receptor or postreceptor defects.
- AGL results from secondary destruction of adipose tissue, with metabolic syndrome as a consequence.
Implications:
- Early mortality is a significant concern, particularly due to cardiac complications in CGL.
- Management strategies focus on reducing energy consumption to mitigate metabolic burden.
- Understanding the distinct etiologies of CGL and AGL is crucial for targeted therapeutic approaches.